After completing a PhD in Biochemical Toxicology at the MRC Toxicology Unit and London University, Andy undertook postdoctoral studies at the University of California and ICI Central Toxicology Laboratory before moving into the Pharmaceutical Industry. Over the past 25+ years Andy has lead DMPK teams in both drug discovery and development for a number of global pharmaceutical companies, including GD Searle, Servier, Fisons, Astra and most recently, AstraZeneca at the Loughborough site. At AZ Andy managed the Inflammatory Projects DMPK Section and created the Biopharmaceutical Bioanalytical Centre of Excellence supporting all AZ Biologics projects in partnership with colleagues at Cambridge Antibody Technology. He has been the DMPK contributor on approximately 100 projects and has been the DMPK contributor to many development product teams over the past 20 years. Andy was engaged in several global teams and advisory groups within AstraZeneca including Productivity Improvement and alignment of cross function working practices (egwith PAR&D and Safety), the MIST advisory team and the AZ Global Biopharmaceuticals Strategy team. In his last 2 years at AZ Andy has been a Global Project Manager with responsibility for taking several early development opportunities through the pre-clinical evaluation phase and into clinical trials in healthy volunteers and patients.
Andy has also been a past chairman of the European industry wide Drug Development Discussion Group and was a lecturer on several of the courses organised by the DMDG over more than 10 years.
Andy is regularly engaged by the Technology Strategy Board as an Assessor of funding applications for the Biomedical Catalyst, Stratified Medicine and SMART competitions.